Loughborough University The Centre for Biological Engineering Doc Ref: FS008.1 : HTA-PR-FORM/007 Acquisition and Receipt of Biological Materials Version N°: 1.0 Issue Date: 15.03.2019

ARF No: CBE/ARF/0039

PART A: To be completed by the	e Receiver (a separat	te form must be	completed fo	r each sampl	e type)			
A1. Details of Sample/Specimer	n							
Type/ID: (eg primary cell, cell line, tiss body fluid, excreta, biological agent)	ue, Frozen PBM	Frozen PBMC aliquots				⊠Human □Animal		
Format / Quantity: (eg vials, slides,	etc) 80* cryovial	80* cryovials						
Tissue site/Organ source:	PBMCs	PBMCs						
Batch N°:	ax3418, 341	ax3418, 3418013019C						
Is the sample/specimen considered to be Relevant Material under the Human Tissue Act (HTA)? If No, go to section A2.								
Is the material obtained from an HTA licenced Tissue Bank with REC approval for generic research use?								
Is the material obtained for storage and use under a project specific NHS REC approval?								
Is the material licensable under the HTA? Indicate source below:						⊠Yes □No		
☐HTA licensed organisation ☐Commercial Supplier ☐Imported (from outside England, Wales or N.Ireland)								
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID				Assigned Unique ID (Procuro): S00134116 S00134120				
If Yes, provide Project Ref N°:	J13772	J13772						
If Yes, provide the name of the F								
A2. Details of Receipt								
Date/Time of receipt	Date	15/03/2019		Time:	13.00 pm			
ID of Receiver	Name:	Maryam Shariatzadeh		Dept:	Centre for Biological Engineering			
ID of Supplier/Provider	Name:	Cambridge Bioscience, research Donors LTD		Country:	UK			
PART B: To be completed by the Receiver								
B1. Inspection and Quarantine								
Has a biological risk assessment for the use of this material been approved?		⊠Yes □No	Ref Number:154					
Physical integrity of the materia	⊠Yes □No	If No, describe action taken						
Quantity received correct?	⊠Yes □No	If No, describe action taken						
Labelling correct and legible?	⊠Yes □No	If No, describe action taken						
Is the relevant documentation attached to this form?	C of A or equivalen quality	t evidence of	⊠Yes □No □N/A					
	Agreements to enable transfer of material eg MTA, SLA		□Yes □No ⊠N/A					

If No, add reference or details to ensure traceability	rails Details/evidence/assurance of ⊠Yes □No □I consent		⊠Yes □No □N/A					
,	Other (describe	be) □Yes □No 図N/A						
	Building/Room							
Temporary storage -			# / / ·					
	Storage Unit ID							
Quarantine location (as applicable)	Within storage unit location ID							
	Date/Time of quarantine							
Submitted by:	Signature:		Date:	<u>1</u>				
Total Control of the	Maryam Shariat	zadeh	15.03.2019					
PART C: To be completed by the departmental Quality Manager								
C1. Quality Assurance Checks								
Has the sample/specimen been	□Yes □No □N/A							
Has the donor been screened fo	☐Yes □No □N/A							
Has the sample/specimen been	□Yes □No □N/A							
Is there evidence that the suppli standards or other recognised or	☐Yes □No □N/A							
For HTA licensable material, is the storage and use of the material	✓Yes □No □N/A							
Is there sufficient evidence to su	□Yes □No □N/A							
C2. Approval for release from quarantine								
Can the material be released fro released for processing?	□Yes □No							
		Accept as is, bu	ut with extra controls					
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐Rework or represent specified requires	ocess to meet the ments	50 				
		☐Test to meet sp	pecified requirements					
		☐Return to supp	lier/provider					
delication of the second		□Disposal						
		Building/Room						
		Storage Unit ID						
If Yes, provide details of storage applicable)	location (as	Within storage unit location ID						
		Database Referer	nce					
Andrew Commencer (Commencer)		Date/Time of transfer						
Approved by:		Signature:	~ A	Date:				
C. Kavana	<u>g</u> h	8		19/1/19				